The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").
The Fund is based at Alderley Park, which is well recognised as a site of national importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.
Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics).
The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.
We will invest in ‘Life Science’ businesses across the following sectors:
- Life Science contract research organisations (CRO)
- Healthcare technologies
- Medical devices
With contributions from both private and public sector partners, the size of the Fund, at first close, is around £31m.